|
1
|
Chen R, Smith-Cohn M, Cohen AL and Colman H: Glioma subclassifications and their clinical significance. Neurotherapeutics. 14:284–297. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wesseling P, Kros JM and Jeuken JWM: The pathological diagnosis of diffuse gliomas: Towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. Diagnostic Histopathology. 17:486–494. 2011.
|
|
3
|
Kristensen BW, Priesterbach-Ackley LP, Petersen JK and Wesseling P: Molecular pathology of tumors of the central nervous system. Ann Oncol. 30:1265–1278. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Brandner S and von Deimling A: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol. 41:694–720. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Diwanji TP, Engelman A, Snider JW and Mohindra P: Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 8:99–113. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fuller GN and Scheithauer BW: The 2007 revised world health organization (WHO) classification of tumours of the central nervous system: Newly codified entities. Brain Pathol. 17:304–307. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, et al: International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24:429–435. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M and Hormigo A: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 88:293–298. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W and van den Bent M: cIMPACT-NOW update 1: Not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol. 135:481–484. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K and Delattre JY: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA and van den Bent MJ: 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 42:2499–2503. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, et al: Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: Use with caution. Mod Pathol. 26:922–929. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Garman RH: Histology of the central nervous system. Toxicol Pathol. 39:22–35. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wiedenmann B, Franke WW, Kuhn C, Moll R and Gould VE: Synaptophysin: A marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA. 83:3500–3504. 1986.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Choi BH and Khang SK: Immunohistochemical Expression of Synaptophysin in Brain Tumors. The Korean Journal of Pathology, 35: 433-439.
|
|
20
|
van den Bent MJ: Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol. 120:297–304. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS and Lothe RA: Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet. 127:64–70. 2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Torres-Martin M, Pena-Granero C, Carceller F, Gutiérrez M, Burbano RR, Pinto GR, Castresana JS, Melendez B and Rey JA: Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. Mol Cytogenet. 7(1)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schoonjans F, Zalata A, Depuydt CE and Comhaire FH: MedCalc: A new computer program for medical statistics. Comput Methods Programs Biomed. 48:257–262. 1995.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, et al: Farewell to oligoastrocytoma: In situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 128:551–559. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, et al: Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 132:625–634. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Iuchi T, Sugiyama T, Ohira M, Kageyama H, Yokoi S, Sakaida T, Hasegawa Y, Setoguchi T and Itami M: Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 35:71–80. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, et al: cIMPACT-NOW update 3: Recommended diagnostic criteria for ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.’. Acta Neuropathol. 136:805–810. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, et al: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 372:2499–2508. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, et al: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 129:679–693. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent AJPE and van den Bent MJ: Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: Assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol. 134:957–959. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B and Hainfellner JA: Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 70:715–723. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Losman JA and Kaelin WG Jr: What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27:836–852. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ye D, Ma S, Xiong Y and Guan KL: R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell. 23:274–276. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bush NA and Butowski N: The effect of molecular diagnostics on the treatment of glioma. Curr Oncol Rep. 19(26)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lipp ES and McLendon RE: Tissue is the issue: Biomarkers of prognosis and classification in adult gliomas. Semin Oncol Nurs. 34:430–442. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Stoyanov GS, Dzhenkov DL, Kitanova M, Donev IS and Ghenev P: Correlation between Ki-67 index, World health organization grade and patient survival in glial tumors with astrocytic differentiation. Cureus. 9(e1396)2017.PubMed/NCBI View Article : Google Scholar
|
